Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Osteosong, also known by its Pinyin name Gusongbao, is a Traditional Chinese Medicine (TCM) formulation primarily indicated for the treatment of bone-related disorders, including osteoporosis, osteoarthritis, and skeletal fluorosis. It is a multi-ingredient botanical product developed in China, with significant research and clinical evaluation conducted by institutions such as Guizhou Medical University. The formulation typically consists of a blend of herbal extracts, including *Epimedium brevicornu* (Herba Epimedii), *Dipsacus asper* (Radix Dipsaci), *Rehmannia glutinosa*, *Anemarrhena asphodeloides*, *Psoralea corylifolia*, and *Astragalus membranaceus*. Osteosong is designed to modulate bone metabolism by promoting osteoblast proliferation and differentiation while inhibiting osteoclast activity, thereby increasing bone mineral density and alleviating bone pain. In the context of endemic skeletal fluorosis, it is studied for its potential to mitigate radiographic changes and improve physical function in patients suffering from chronic fluoride toxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Osteosong.